Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide is a synthetic corticosteroid with potent anti-inflammatory properties. It acts primarily as a glucocorticoid receptor agonist and is used to treat various inflammatory diseases affecting the airways and gastrointestinal tract. Budesonide works by inhibiting multiple types of inflammatory cells (such as mast cells and eosinophils) and suppressing the release of inflammatory mediators like histamine and cytokines. It has high topical anti-inflammatory activity with minimal systemic effects due to extensive first-pass metabolism in the liver. Budesonide is indicated for conditions such as asthma (inhaled), chronic obstructive pulmonary disease (COPD), Crohn's disease (oral), ulcerative colitis (oral/rectal), eosinophilic esophagitis (oral suspension/tablet), primary immunoglobulin A nephropathy (oral delayed-release capsule), autoimmune hepatitis (oral capsule/granule), allergic rhinitis/nasal polyps (nasal spray), and microscopic colitis[1][2][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide.